Found 42 clinical trials
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
Background: Peripheral blood stem cell transplantation procedures are used for people with sickle cell disease. Researchers want to improve the success and reduce the complications for these procedures. This might allow more people to have a transplant. Objective: To see if a new transplant regime is effective, safe and well …
- 57 views
- 22 Dec, 2020
- 1 location
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
- 74 views
- 25 Mar, 2021
- 1 location
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab Busulfan and TBI With Post-Transplant Cyclophosphamide
Background CGD causes infections and inflammation. The only cure currently is a bone marrow transplant. Most often a perfectly matched bone marrow donor is used. Researchers want to see if they can lower the risks of using a mismatched donor. Objectives To see if it is safe to use a …
- 1 views
- 28 Jun, 2021
- 1 location
Allograft for Sickle Cell Disease and Thalassemia
ablation. If the graft is rejected, the patient will reconstitute autologous marrow function. We will use a combination of low dose irradiation, Alemtuzumab (Campath), and sirolimus. Peripheral
- 28 views
- 18 Feb, 2021
- 1 location
RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS
immunomodulatory medication. The study has two treatment arms; arm A: HSCT (hematopoietic stem cell transplantation) and arm B: alemtuzumab, a registered immunomodulatory treatment of RRMS. A pre-planned 3-year
- 35 views
- 19 Feb, 2021
- 9 locations
Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
The investigators designed a compassionate basis phase II study for refractory/relapsed mycosis fungoides/Sezary syndrome consisting of alemtuzumab (Campath) for primary evaluation of
- 54 views
- 07 Nov, 2020
- 1 location
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense CHOP-14 in patients
- 10 views
- 07 Nov, 2020
- 1 location
Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
monoclonal antibody Campath 1−H (Alemtuzumab) followed by long−term maintenance with the Calcineurin inhibitor Tacrolimus The recent development (and licensing in the UK) of an extended−release
- 22 views
- 07 Nov, 2020
- 1 location
Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure
RATIONALE: Immunosuppressive therapies, such as alemtuzumab and cyclosporine, may improve bone marrow function and increase blood cell counts. Giving alemtuzumab together with
- 44 views
- 07 Nov, 2020
- 1 location
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the
- 0 views
- 27 Jun, 2021
- 1 location